Loading
A phase 1/2 trial of Pembrolizumab, Sacituzumab tirumotecan, Capecitabine, Fluorouracil (5-FU), Oxaliplatin and Patritumab deruxtecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) is a phase 1/2 interventional study registered as NCT06469944 by Merck Sharp & Dohme LLC, with 160 participants planned, started 2024-09-20 and due to reach its primary completion in 2029-09-12. Interventions recorded: Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin and 5-Fluorouracil (5-FU).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, Oxaliplatin, Fluorouracil (5-FU), Merck & Co. (MSD) and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Oesophageal cancer and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Pembrolizumab and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Capecitabine, Pembrolizumab and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Capecitabine, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Gastric & gastro-oesophageal junction cancer, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/